A practical guide for clinicians on cannabis use by IBD patients, including clinical vignettes

While cannabis may help manage some IBD symptoms, it has not been proven to reduce inflammation, and clinicians should be aware of dosing inconsistencies, dependence risks, and cannabinoid hyperemesis syndrome.

Buckley, Megan C et al.·Advances in therapy·2021·Preliminary EvidenceReview
RTHC-03030ReviewPreliminary Evidence2021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Cannabis has gained popularity for IBD symptom management but has not been proven to reduce inflammation or correct underlying disease processes. Key concerns include dosing inconsistencies across products, risk of dependence, and cannabinoid hyperemesis syndrome.

Key Numbers

15 U.S. states regulate adult cannabis use; 36 states for medical use; cannabis has not been proven to help with IBD inflammation

How They Did This

Review article summarizing current research on cannabis and IBD, supplemented with clinical vignettes illustrating practical considerations for clinicians.

Why This Research Matters

As more IBD patients turn to cannabis, clinicians need practical guidance on discussing its potential benefits and limitations, especially distinguishing symptom relief from disease modification.

The Bigger Picture

The disconnect between patient enthusiasm for cannabis and the limited evidence for its efficacy in IBD represents a common pattern across many chronic conditions where patients seek alternatives to conventional treatment.

What This Study Doesn't Tell Us

Narrative review without systematic methodology. Clinical vignettes illustrate but do not provide evidence. Limited by the small number of available clinical studies on cannabis for IBD.

Questions This Raises

  • ?Should gastroenterologists proactively discuss cannabis with IBD patients?
  • ?How should clinicians monitor patients who use cannabis alongside IBD medications?
  • ?What standardized guidance can be developed for this common clinical scenario?

Trust & Context

Key Stat:
Cannabis has not been proven to reduce IBD inflammation
Evidence Grade:
Narrative review with clinical vignettes for practical guidance
Study Age:
Published in 2021. Cannabis use among IBD patients continues to increase as access expands.
Original Title:
Inflammatory Bowel Disease and Cannabis: A Practical Approach for Clinicians.
Published In:
Advances in therapy, 38(7), 4152-4161 (2021)
Database ID:
RTHC-03030

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Should IBD patients use cannabis?

Cannabis may help manage some symptoms like pain, but has not been proven to reduce the inflammation underlying IBD. Patients should discuss potential benefits and risks with their gastroenterologist.

What risks should IBD patients know about cannabis?

Key concerns include dosing inconsistencies between products, risk of dependence with chronic use, and cannabinoid hyperemesis syndrome, which paradoxically causes severe vomiting in some chronic users.

Read More on RethinkTHC

Cite This Study

RTHC-03030·https://rethinkthc.com/research/RTHC-03030

APA

Buckley, Megan C; Kumar, Anand; Swaminath, Arun. (2021). Inflammatory Bowel Disease and Cannabis: A Practical Approach for Clinicians.. Advances in therapy, 38(7), 4152-4161. https://doi.org/10.1007/s12325-021-01805-8

MLA

Buckley, Megan C, et al. "Inflammatory Bowel Disease and Cannabis: A Practical Approach for Clinicians.." Advances in therapy, 2021. https://doi.org/10.1007/s12325-021-01805-8

RethinkTHC

RethinkTHC Research Database. "Inflammatory Bowel Disease and Cannabis: A Practical Approac..." RTHC-03030. Retrieved from https://rethinkthc.com/research/buckley-2021-inflammatory-bowel-disease-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.